4.5 Article

The potential economic value of a hookworm vaccine

Journal

VACCINE
Volume 29, Issue 6, Pages 1201-1210

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.12.004

Keywords

Hookworm vaccine; Economics; Computer simulation

Funding

  1. Bill and Melinda Gates Foundation
  2. National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) [1U54GM088491-0109]

Ask authors/readers for more resources

Hookworm infection is a significant problem worldwide. As development of hookworm vaccine proceeds, it is essential for vaccine developers and manufacturers, policy makers, and other public health officials to understand the potential costs and benefits of such a vaccine. We developed a decision analytic model to evaluate the cost-effectiveness of introducing a hookworm vaccine into two populations in Brazil: school-age children and non-pregnant women of reproductive age. Results suggest that a vaccine would provide not only cost savings, but potential health benefits to both populations. In fact, the most cost-effective intervention strategy may be to combine vaccine with current drug treatment strategies. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Surgery

A comparative cost-utility analysis of postoperative calcium supplementation strategies used in the current management of hypocalcemia

Kristina J. Nicholson, Kenneth J. Smith, Kelly L. McCoy, Sally E. Carty, Linwah Yip

SURGERY (2020)

Article Nutrition & Dietetics

Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria

Vikram K. Raghu, David G. Binion, Kenneth J. Smith

AMERICAN JOURNAL OF CLINICAL NUTRITION (2020)

Article Infectious Diseases

Trichomonas vaginalis, endometritis and sequelae among women with clinically suspected pelvic inflammatory disease

Ann E. Wiringa, Roberta B. Ness, Toni Darville, Richard H. Beigi, Catherine L. Haggerty

SEXUALLY TRANSMITTED INFECTIONS (2020)

Article Geriatrics & Gerontology

Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations

Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2020)

Article Surgery

Economic analysis of screening for subclinical rejection in kidney transplantation using protocol biopsies and noninvasive biomarkers

Chethan M. Puttarajappa, Rajil B. Mehta, Mark S. Roberts, Kenneth J. Smith, Sundaram Hariharan

Summary: The study found that screening for subclinical rejection more than once during the first year after kidney transplantation is not economically reasonable, with a one-time screening at peak incidence being the preferred option. Screening with protocol biopsy was favored over using biomarkers.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Article Immunology

Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? A value of information analysis

Angela R. Wateska, Mary Patricia Nowalk, Hawre Jalal, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith

Summary: The study indicates that further research on parameters of pneumococcal vaccine uptake programs is not supported at commonly cited US cost-effectiveness benchmarks in adults. It is justifiable to conduct further research to reduce uncertainty in other aspects of adult pneumococcal vaccination.

VACCINE (2021)

Article Immunology

Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis

Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman

Summary: The COVID-19 pandemic has led to declines in childhood PCV13 vaccination rates, which could result in increased pneumococcal disease rates in seniors, impacting the economic favorability of PCV13 vaccination in older adults. Absolute decreases of over 50% in pediatric PCV13 vaccination over a two-year period would be needed to make intensified PCV13 use economically favorable in non-immunocompromised seniors.

VACCINE (2021)

Article Clinical Neurology

Imaging versus Intervention in Managing Small Unruptured Intracranial Aneurysms: A Cost-Effectiveness Analysis

Clark A. Veet, Stephen Capone, David Panczykowski, Natasha Parekh, Kenneth J. Smith, Dong H. Kim, H. Alex Choi, Spiros L. Blackburn

Summary: The study found that immediate surgical treatment is the most cost-effective strategy for small unruptured anterior circulation aneurysms, particularly in patients under 70 years of age. The cost-effectiveness of immediate surgery is highly sensitive to factors such as diagnosis age, rupture rate, and surgical complication risk.

CEREBROVASCULAR DISEASES (2022)

Article Health Care Sciences & Services

Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes

Margaret F. Zupa, Ronald A. Codario, Kenneth J. Smith

Summary: The study found that for patients with Type 2 diabetes and cardiovascular disease, semaglutide is likely to be more cost-effective than empagliflozin added to usual treatment.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)

Article Oncology

Effects of an Oncology Nurse-Led, Primary Palliative Care Intervention (CONNECT) on Illness Expectations Among Patients With Advanced Cancer

Lauren E. Sigler, Andrew D. Althouse, Teresa H. Thomas, Robert M. Arnold, Douglas White, Thomas J. Smith, Edward Chu, Margaret Rosenzweig, Kenneth J. Smith, Yael Schenker

Summary: This study assessed the effect of an oncology nurse-led primary palliative care intervention on illness expectations among patients with advanced cancer. The results showed little difference in realistic illness expectations at 3 months between the intervention and standard care groups. The study suggests that illness expectations are difficult to change among patients with advanced cancer.

JCO ONCOLOGY PRACTICE (2022)

Article Nutrition & Dietetics

Current practices in lipid emulsion utilization in the prevention and treatment of intestinal failure-associated liver disease: A survey of pediatric intestinal rehabilitation and transplant centers

Vikram K. Raghu, Wednesday M. A. Sevilla, Dale E. King, Feras Alissa, Scott Rothenberger, Kenneth J. Smith, Simon P. Horslen, Jeffrey A. Rudolph

Summary: Centers for intestinal rehabilitation and transplantation commonly use alternative intravenous lipid emulsions (ILEs), which is significant for decision support in specific clinical scenarios.

JOURNAL OF PARENTERAL AND ENTERAL NUTRITION (2022)

Article Infectious Diseases

Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA

Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman

Summary: The general population recommendations for PCV20 use are more economically reasonable for both Black and non-Black older adult populations compared to PCV15/PPSV23. If a single vaccine can increase the uptake, especially in underserved populations, the use of PCV20 becomes even more favorable.

INFECTIOUS DISEASES AND THERAPY (2022)

Article Immunology

Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults

Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith

Summary: The introduction summarizes the CDC's recommendations for pneumococcal vaccination in older adults and the potential benefits of an in-development 21-valent vaccine (PCV21) compared to current recommendations. A decision model was used to compare the cost-effectiveness of PCV21 to current vaccines in Black and non-Black cohorts. The results indicate that PCV21 is likely to be economically and clinically favorable in older adults.

VACCINE (2023)

Article Economics

Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older

Shoroq M. Altawalbeh, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith

Summary: This study estimated the societal cost of racial disparities in pneumococcal disease among US adults aged >= 50 years. The findings suggest that the racial disparities in costs are substantial and implementing policies and interventions could reduce these costs and improve health.

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2023)

Article Health Policy & Services

Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged<65 Years

Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith

JOURNAL OF COMMUNITY HEALTH (2020)

No Data Available